Status:
COMPLETED
Diagnostic Value of DWI-MRI for Detection of Peritoneal Metastases in High-risk Pancreatic Ductal Adenocarcinoma.
Lead Sponsor:
Laval University
Conditions:
Pancreas Cancer, Duct Cell Adenocarcinoma
Pancreas Adenocarcinoma
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Diffusion-weighted magnetic resonance imaging (DWI/MRI) has been described in recent literature as a highly sensitive and specific modality for the detection of peritoneal metastases (PM). It has been...
Detailed Description
This is a prospective study from a single center. Patients will be evaluated and operated on by one of five surgeons with a subspeciality in hepato-biliary and pancreatic surgery. After thorough asses...
Eligibility Criteria
Inclusion
- Confirmed diagnosis of pancreatic ductal adenocarcinoma.
- Resectable disease or borderline resectable disease based on CT.
- Tumor size ≥ 3 cm.
- CA 19-9 ≥ 400 U/mL with normal bilirubin level (\< 40)
- No evidence of distant metastases.
- Patient fit for pancreatic resection (ECOG 0 or 1).
Exclusion
- Impossibility to obtain tissue diagnosis preoperatively confirming pancreatic ductal adenocarcinoma.
- Locally advanced disease on CT.
- Tumor size \< 3 cm.
- CA 19-9 \< 400 U/mL or CA 19-9 ≥ 400 U/mL with no preoperative drainage.
- Suspicion of distant metastases, including peritoneal metastases, on CT.
- Patient who is unable to have MRI.
- Patient unfit for pancreatic resection (ECOG 2 or more).
Key Trial Info
Start Date :
March 28 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 30 2024
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT05340569
Start Date
March 28 2022
End Date
September 30 2024
Last Update
March 20 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU de Québec
Québec, Quebec, Canada, G1R 2J6